Dr. Marc Penn directs the medical research of Tissue Genesis. In addition, Dr. Penn is CEO of Black Beret Life Sciences, providing oversight and management of the life sciences investments of the Bosarge Family Office and the executive teams of the portfolio companies in the areas of regenerative medicine, anti-aging and immune therapies.
Anton Krucky served as CEO and President of Tissue Genesis for its first 17 years, positioning Tissue Genesis as a respected and forward-looking leader in regenerative medicine, and now serves on the Board of Managers. Mr. Krucky is a former IBM executive and served as General Manager of Operations for IBM Pacific. He has extensive global management and executive experience in product development, marketing, and sales.
As Director of Operational Management for Black Beret Life Sciences (BBLS), Ben Chlebina supports the operational, strategic planning, financial and marketing efforts of the BBLS management and portfolio companies to optimize growth and maximize value.
An internationally recognized expert in vascular biology and tissue engineering, Dr. Stuart Williams is a leader in endothelial cell isolation technology. He is credited with developing and patenting the technique for isolating human stem cells from fat tissue.
Dr. Paul Kosnik is responsible for business development and managing interactions with the clinical trial sites and medical experts. He also serves as the Tissue Genesis Principal Investigator for the Critical Limb Ischemia trial funded by the federal government.
Dr. Rolf Wolters is responsible for Product Development and Product Management at Tissue Genesis. He is also the Principal Investigator for the Department of Defense phase II SBIR for advanced cell isolation technology (NIMBUS Project).
Cristine Kosnik is the Director of Quality Assurance at Tissue Genesis responsible for the management of design controls, documentation, corrective and preventive action, customer feedback, production, and validation.
Mr. Mike Winegar has over thirty years of experience in global medical device regulatory affairs, regulatory compliance, quality assurance, and clinical research, with an emphasis on neurovascular, cardiovascular, and peripheral vascular technologies. Mr. Winegar guides the Tissue Genesis regulatory affairs activities.